J&J lupus drug meets primary endpoint in Phase 2 study (JNJ:NYSE)
· seekingalpha.com
Johnson & Johnson says nipocalimab cut lupus disease activity in Phase 2 and sustained benefits through 1 year.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...